Jiangsu Alphamab Biopharmaceuticals Co., Ltd clinical trials
A subsidiary of Alphamab Oncology
The registry lists 38 studies whose lead sponsor is Jiangsu Alphamab Biopharmaceuticals Co., Ltd. 16 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 1, 2026.
Registry sponsor names on this page
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd38 studies
Something wrong with this grouping? Tell us on the Alphamab Oncology page.
Studies
Recruiting first, then most recently updated. Showing 38 of 38. All Alphamab Oncology studies →
- JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical CancerNot yet recruitingNCT07797153Phase 3
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- A Phase I Study of JSKN021 in Advanced Solid TumorsRecruitingNCT07617727Phase 1
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of CareRecruitingNCT07533123Phase 3
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Evaluation of JSKN016 Combination Therapy in Subjects With NSCLCRecruitingNCT06868732Phase 1
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- JSKN033 Combination Therapy in Subjects With Advanced Cervical CancerNot yet recruitingNCT07497074Phase 2
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- JSKN016HC in Patients With Advanced or Metastatic Solid Malignant TumorsNot yet recruitingNCT07475559Phase 1
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- A Study of JSKN027 in Patients With Advanced Solid TumorsNot yet recruitingNCT07391644Phase 1
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast CancerNot yet recruitingNCT07336771Phase 1/2
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- JSKN022 in Subjects With Advanced Malignant Solid TumorsRecruitingNCT07292402Phase 1
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung CancerNot yet recruitingNCT07283198Phase 2
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast CancerRecruitingNCT06942234Phase 1/2
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer SubjectsRecruitingNCT06079983Phase 3
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance: a Phase II Clinical StudyNot yet recruitingNCT06775483Phase 2
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- JSKN033 in Chinese Subjects with Advanced Malignant TumorsNot yet recruitingNCT06770881Phase 1/2
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian CancerNot yet recruitingNCT06751485Phase 3
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid TumorsRecruitingNCT06592417Phase 1
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Study of KN046 in Subjects With Advanced Non-Small Cell Lung CancerCompletedNCT05420220Phase 2
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid TumorsActive, not recruitingNCT05744427Phase 1/2
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- JSKN033 in Patients With Advanced or Metastatic Solid Malignant TumorsTerminatedNCT06226766Phase 1/2
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Clinical Study of KN052 in Chinese Subjects With Advanced Solid TumorsTerminatedNCT05309512Phase 1
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.Active, not recruitingNCT05149326Phase 3
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction CancerCompletedNCT03925974Phase 2
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic CarcinomaTerminatedNCT04469725Phase 2
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric CancerCompletedNCT03619681Phase 1
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid TumorsCompletedNCT04521179Phase 2
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast CancerActive, not recruitingNCT04165993Phase 2
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast CancerTerminatedNCT04778982
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- KN046 in Subjects With Advanced Solid Tumors and LymphomaCompletedNCT03733951Phase 1
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast CancerCompletedNCT03872791Phase 1/2
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 AgentTerminatedNCT05001724Phase 2/3
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- KN046 in Patients With Advanced Non-small Cell Lung CancerTerminatedNCT03838848Phase 2
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Efficacy and Safety Study of KN019 in Rheumatoid Arthritis Patients With an Inadequate Response to MethotrexateCompletedNCT04038970Phase 2
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular CarcinomaTerminatedNCT04601610Phase 1/2
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- KN046 in Subjects With Late Stage Esophageal Squamous Cell CarcinomaCompletedNCT03925870Phase 2
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast CancerStatus unknownNCT04881929Phase 2
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- KN046 in Subjects With Advanced Squamous Non-small Cell Lung CancerStatus unknownNCT04474119Phase 3
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- KN026 in Patients With HER2 Expressing Breast Cancer and Gastric CancerStatus unknownNCT03847168Phase 1
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Study of KN046 With Chemotherapy in First Line Advanced NSCLCStatus unknownNCT04054531Phase 2
Sponsor listed in the registry: Jiangsu Alphamab Biopharmaceuticals Co., Ltd